Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847887 | 0.90 | KDM4E (0.49) | ALDH1A1FDPSSMN1; SMN2MAPTMEN1 | |
| SCHEMBL4855047 | 0.83 | F2RL3 (0.48) | F2RL3F2SMN1; SMN2MAPTGAA | |
| SCHEMBL4851672 | 0.82 | MAPK1 (0.48) | ALDH1A1SMN1; SMN2MAPTGAAMEN1 | |
| SCHEMBL4848215 | 0.81 | ALDH1A1 (0.53) | ALDH1A1F2RL3FDPSSMN1; SMN2MAPT | |
| SCHEMBL4850499 | 0.78 | F2RL3 (0.42) | F2RL3F2SMN1; SMN2MAPTGAA | |
| SCHEMBL4845955 | 0.74 | ALDH1A1 (0.51) | ALDH1A1FDPSSMN1; SMN2MAPTMEN1 | |
| SCHEMBL4848311 | 0.73 | ALDH1A1 (0.46) | ALDH1A1F2RL3F2SMN1; SMN2MAPT | |
| SCHEMBL4048998 | 0.72 | ALDH1A1 (0.65) | ALDH1A1FDPSSMN1; SMN2MAPTKMT2A | |
| SCHEMBL29570200 | 0.72 | ALDH1A1 (0.65) | ALDH1A1FDPSSMN1; SMN2MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL5692356 | 0.71 | ALDH1A1 (0.64) | ALDH1A1FDPSSMN1; SMN2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368578-B2 | Five-membered heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20060135578-A1 | Five-membered heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1541564-A1 | FIVE-MEMBERED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135578-A1 | Five-membered heterocyclic compounds | GPR119, OR10J3, CYP11B1 | ALDH1A1 821/4885F2RL3 4515/4885F2 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.